Let’s find a bladder cancer trial for you
Let’s find a bladder cancer trial for you
North is the fastest way to discover and match with one of the 212 bladder cancer trials open in the U.S.
North is the fastest way to discover and match with one of the 212 bladder cancer trials open in the U.S.
How North Works
1
5-10 minute health
history intake
5-10 minute health
history intake
2
We’ll send you personalized match results in 1-2 days
We’ll send you personalized match results in 1-2 days
3
We'll connect you with clinical trial coordinators
We'll connect you with clinical trial coordinators
1
5-10 minute health
history intake
2
We’ll send you personalized
match results in 1-2 days
3
We'll connect you with
clinical trial coordinators
Take the next step
Explore trials near you
0
0
Bladder cancer clinical trials now enrolling in the U.S.
0
0
Metastatic bladder cancer U.S. clinical trials
0
0
Stage IV bladder cancer trials
North's expert research advisors
Dr. Mike Gibson
Dr. Mike Gibson
MD, PhD, Division of Hematology and
Oncology, Vanderbilt-Ingram Cancer Center
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram
Cancer Center
Dr. Carol Tweed
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Board Certified MD, Hematology and
Medical Oncology, Annapolis, Maryland
Holly Hoefer
Holly Hoefer
VP Patient Engagement, Helios
Clinical Research
Dr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
Research
Questions about bladder cancer clinical trials?
What are new treatments for bladder cancer in 2025?
New bladder cancer treatments in 2025:
Inlexzo (gemcitabine intravesical system) — new option for BCG-unresponsive NMIBC.
Enfortumab vedotin + pembrolizumab — newly approved perioperative combo for muscle-invasive bladder cancer.
Durvalumab — expanding use in neoadjuvant/adjuvant settings for muscle-invasive disease.
Emerging options — BCG-combo immunotherapies (e.g., sasanlimab) and drug-delivery devices like TAR-200 showing strong early data.
Sources:
FDA; Targeted Oncology; Mayo Clinic; UroToday
What are new treatments for bladder cancer in 2025?
New bladder cancer treatments in 2025:
Inlexzo (gemcitabine intravesical system) — new option for BCG-unresponsive NMIBC.
Enfortumab vedotin + pembrolizumab — newly approved perioperative combo for muscle-invasive bladder cancer.
Durvalumab — expanding use in neoadjuvant/adjuvant settings for muscle-invasive disease.
Emerging options — BCG-combo immunotherapies (e.g., sasanlimab) and drug-delivery devices like TAR-200 showing strong early data.
Sources:
FDA; Targeted Oncology; Mayo Clinic; UroToday
What are new treatments for bladder cancer in 2025?
New bladder cancer treatments in 2025:
Inlexzo (gemcitabine intravesical system) — new option for BCG-unresponsive NMIBC.
Enfortumab vedotin + pembrolizumab — newly approved perioperative combo for muscle-invasive bladder cancer.
Durvalumab — expanding use in neoadjuvant/adjuvant settings for muscle-invasive disease.
Emerging options — BCG-combo immunotherapies (e.g., sasanlimab) and drug-delivery devices like TAR-200 showing strong early data.
Sources:
FDA; Targeted Oncology; Mayo Clinic; UroToday
What country has the best treatment for bladder cancer?
There’s no single “best” country, but three regions consistently offer the most advanced bladder cancer care, based on access to new drugs, clinical trials, surgical expertise, and survival outcomes:
1. United States
Fast access to newly approved treatments (immunotherapy, antibody-drug conjugates, gene therapy).
Large number of NCI-designated cancer centers and clinical trials.
Strong expertise in robotic cystectomy and bladder-preserving protocols.
2. Germany (and broader Western Europe like the UK & Netherlands)
Excellent urologic surgery outcomes and standardized cancer pathways.
High survival rates for early-stage disease.
Strong integration of chemo-immunotherapy and bladder-sparing approaches.
3. Japan
Among the world leaders in urologic cancer survival statistics.
High adoption of precision surgery and early integration of new therapies.
What country has the best treatment for bladder cancer?
There’s no single “best” country, but three regions consistently offer the most advanced bladder cancer care, based on access to new drugs, clinical trials, surgical expertise, and survival outcomes:
1. United States
Fast access to newly approved treatments (immunotherapy, antibody-drug conjugates, gene therapy).
Large number of NCI-designated cancer centers and clinical trials.
Strong expertise in robotic cystectomy and bladder-preserving protocols.
2. Germany (and broader Western Europe like the UK & Netherlands)
Excellent urologic surgery outcomes and standardized cancer pathways.
High survival rates for early-stage disease.
Strong integration of chemo-immunotherapy and bladder-sparing approaches.
3. Japan
Among the world leaders in urologic cancer survival statistics.
High adoption of precision surgery and early integration of new therapies.
What country has the best treatment for bladder cancer?
There’s no single “best” country, but three regions consistently offer the most advanced bladder cancer care, based on access to new drugs, clinical trials, surgical expertise, and survival outcomes:
1. United States
Fast access to newly approved treatments (immunotherapy, antibody-drug conjugates, gene therapy).
Large number of NCI-designated cancer centers and clinical trials.
Strong expertise in robotic cystectomy and bladder-preserving protocols.
2. Germany (and broader Western Europe like the UK & Netherlands)
Excellent urologic surgery outcomes and standardized cancer pathways.
High survival rates for early-stage disease.
Strong integration of chemo-immunotherapy and bladder-sparing approaches.
3. Japan
Among the world leaders in urologic cancer survival statistics.
High adoption of precision surgery and early integration of new therapies.
What is Pfizer's new drug for bladder cancer?
Pfizer’s newest bladder-cancer therapy is Sasanlimab, a PD-1 immunotherapy now in late-stage development. In 2025, it showed strong Phase III results when combined with BCG for high-risk non–muscle invasive bladder cancer.
Pfizer is also a co-owner of Padcev (enfortumab vedotin) after the Seagen acquisition—now a major frontline and perioperative therapy for advanced bladder cancer when paired with Keytruda.
Sources:
Pfizer press releases (Sasanlimab Phase III results; Padcev–Keytruda data)
What is Pfizer's new drug for bladder cancer?
Pfizer’s newest bladder-cancer therapy is Sasanlimab, a PD-1 immunotherapy now in late-stage development. In 2025, it showed strong Phase III results when combined with BCG for high-risk non–muscle invasive bladder cancer.
Pfizer is also a co-owner of Padcev (enfortumab vedotin) after the Seagen acquisition—now a major frontline and perioperative therapy for advanced bladder cancer when paired with Keytruda.
Sources:
Pfizer press releases (Sasanlimab Phase III results; Padcev–Keytruda data)
What is Pfizer's new drug for bladder cancer?
Pfizer’s newest bladder-cancer therapy is Sasanlimab, a PD-1 immunotherapy now in late-stage development. In 2025, it showed strong Phase III results when combined with BCG for high-risk non–muscle invasive bladder cancer.
Pfizer is also a co-owner of Padcev (enfortumab vedotin) after the Seagen acquisition—now a major frontline and perioperative therapy for advanced bladder cancer when paired with Keytruda.
Sources:
Pfizer press releases (Sasanlimab Phase III results; Padcev–Keytruda data)
What is the biggest contributor to bladder cancer?
The biggest contributor to bladder cancer is smoking.
Cigarette smoke accounts for about half of all bladder cancer cases, making it the strongest and most consistently proven risk factor.
Other contributors exist (chemical exposures, age, sex, chronic inflammation), but none come close to the impact of smoking.
What is the biggest contributor to bladder cancer?
The biggest contributor to bladder cancer is smoking.
Cigarette smoke accounts for about half of all bladder cancer cases, making it the strongest and most consistently proven risk factor.
Other contributors exist (chemical exposures, age, sex, chronic inflammation), but none come close to the impact of smoking.
What is the biggest contributor to bladder cancer?
The biggest contributor to bladder cancer is smoking.
Cigarette smoke accounts for about half of all bladder cancer cases, making it the strongest and most consistently proven risk factor.
Other contributors exist (chemical exposures, age, sex, chronic inflammation), but none come close to the impact of smoking.
What is the gold standard treatment for bladder cancer?
The "gold standard" treatment for bladder cancer depends on whether it is non–muscle invasive or muscle invasive:
Non–Muscle Invasive Bladder Cancer (NMIBC)
Gold standard:
Transurethral resection of the bladder tumor (TURBT)
+ intravesical therapy, most commonly BCG for high-risk disease.
BCG remains the benchmark first-line therapy worldwide.
Muscle-Invasive Bladder Cancer (MIBC)
Gold standard (most established approach):
Radical cystectomy (removal of bladder)
+ platinum-based neoadjuvant chemotherapy (usually cisplatin).
Bladder-Preserving Alternative (for select patients)
A widely accepted gold-standard alternative to surgery for those eligible:
Trimodal therapy:
TURBT + chemotherapy + radiation to preserve the bladder.
Talk to your doctor to see if any of these treatment options would work for you.
What is the gold standard treatment for bladder cancer?
The "gold standard" treatment for bladder cancer depends on whether it is non–muscle invasive or muscle invasive:
Non–Muscle Invasive Bladder Cancer (NMIBC)
Gold standard:
Transurethral resection of the bladder tumor (TURBT)
+ intravesical therapy, most commonly BCG for high-risk disease.
BCG remains the benchmark first-line therapy worldwide.
Muscle-Invasive Bladder Cancer (MIBC)
Gold standard (most established approach):
Radical cystectomy (removal of bladder)
+ platinum-based neoadjuvant chemotherapy (usually cisplatin).
Bladder-Preserving Alternative (for select patients)
A widely accepted gold-standard alternative to surgery for those eligible:
Trimodal therapy:
TURBT + chemotherapy + radiation to preserve the bladder.
Talk to your doctor to see if any of these treatment options would work for you.
What is the gold standard treatment for bladder cancer?
The "gold standard" treatment for bladder cancer depends on whether it is non–muscle invasive or muscle invasive:
Non–Muscle Invasive Bladder Cancer (NMIBC)
Gold standard:
Transurethral resection of the bladder tumor (TURBT)
+ intravesical therapy, most commonly BCG for high-risk disease.
BCG remains the benchmark first-line therapy worldwide.
Muscle-Invasive Bladder Cancer (MIBC)
Gold standard (most established approach):
Radical cystectomy (removal of bladder)
+ platinum-based neoadjuvant chemotherapy (usually cisplatin).
Bladder-Preserving Alternative (for select patients)
A widely accepted gold-standard alternative to surgery for those eligible:
Trimodal therapy:
TURBT + chemotherapy + radiation to preserve the bladder.
Talk to your doctor to see if any of these treatment options would work for you.
How North Helps
Highly curated trial matches only
Highly curated trial matches only
Most trial finders ask you to do the work of searching and filtering for a match.
Most trial finders ask you to do the work of searching and filtering for a match.
Less jargon, more real talk
Less jargon, more real talk
We translate matches from medical-speak into plain English so that you can understand them.
We translate matches from medical-speak into plain English so that you can understand them.
Human introductions to sites
Human introductions to sites
Instead of cold referrals, we make personal introductions to site coordinators near you.
Instead of cold referrals, we make personal introductions to site coordinators near you.
Why consider a trial?
Access new treatments
Access new treatments
Try promising therapies not yet available outside of the trial.
Try promising therapies not yet available outside of the trial.
Advance cancer research
Advance cancer research
Help move science forward for future patients like you.
Help move science forward for future patients like you.
Understand your options
Understand your options
Explore the possibilities before making treatment decisions.
Explore the possibilities before making treatment decisions.
Questions about North
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
